检索结果-南通市图书馆

The impact of intra-operative cell salvage during open nephrectomy

Asian Journal of Urology 2019年第4期6卷 346-352页

作者： Ned Kinnear lina Hua bridget Heijkoop Derek Hennessey Daniel Spernat Department of Urology The Queen Elizabeth HospitalAdelaideAustralia Department of Urology Craigavon Area HospitalPortadownUK

Objective:To assess the impact of intra-operative cell salvage on outcomes in open ***:A retrospective cohort study was performed of all patients undergoing open nephrectomy for suspected malignancy from 1 October 2013 to 1 October *** were grouped and compared based on whether they received intra-operative cell salvage(ICS).Primary outcomes were allogeneic transfusion rates(ATRs),and if histology confirmed cancer,disease *** outcomes were complications and transfusion-related ***:Forty patients underwent open nephrectomy for suspected malignancy during the enrolment *** patients received ICS while 24 did not(standard group).Compared with the standard group,ICS patients had similar median age(63.5 vs.61.0 years;p=0.83)but fewer females(19%vs.58%;p=0.013).The groups were similar in pre-operative and discharge haemoglobin,Charlson Comorbidity Index,length of hospital stay and proportion with thoracoabdominal surgical *** ICS group had a smaller proportion undergoing partial nephrectomy(19%vs.54%;p=0.025)and shorter median follow-up(278 vs.827 days;p=0.0005).Histology was malignant for 14 ICS and 15 standard *** ICS group had more frequentT2 disease(79%vs.27%;p=0.005).There were no positive *** groups had similar ATRs(6%vs.4%;p=0.96),complication rates(19%vs.29%;p=0.46)and recurrence rates(18%vs.7%;p=0.40).Transfusion costs were higher amongst ICS patients(AUD$878.18 vs.$49.65 per patient).Conclusion:ICS appears safe,with low rates of recurrence and *** groups had low ATRs,and therefore cost benefit for ICS was not seen.

关键词： Nephrectomy Cell salvage Autologous Transfusion Blood Cost

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

引用

Signal Transduction and Targeted Therapy 2022年第3期7卷 856-868页

作者： Qi Zhang bridget riley-gillis.lina han Yanan Jia Alessia Lodi Haijiao Zhang Saravanan Ganesan Rongqing Pan Sergej N.Konoplev Shannon R.Sweeney Jeremy A.Ryan Yulia Jitkova Kenneth Dunner Jr Shaun E.Grosskurth Priyanka Vijay Sujana Ghosh Charles Lu Wencai Ma Stephen Kurtz Vivian R.Ruvolo Helen Ma Connie CWeng Cassandra LRamage Natalia Baran Ce Shi Tianyu Cai Richard Eric Davis Venkata L.Battula Yingchang Mi Jing Wang Courtney D.DiNardo Michael Andreeff Jeffery W.Tyner Aaron Schimmer Anthony Letai Rose Ann Padua Carlos E.Bueso-Ramos Stefano Tiziani Joel Leverson Relja Popovic Marina Konopleva Department of Leukemia The University of Texas MD Anderson Cancer CenterHoustonTXUSA AbbVie Inc. North ChicagoILUSA Institute of Hematology Chinese Academy of Medical Sciences&Peking Union Medical CollegeTianjinChina Department of Nutritional Sciences Department of PediatricsDepartment of OncologyDell Medical SchoolThe University of Texas at AustinAustinTX 78712USA Department of Cell Developmental&Cancer BiologyDivision of Hematology&Medical OncologyKnight Cancer InstituteOregon Health&Science UniversityPortlandORUSA Universite de Paris Institut de la Recherche Saint-Louis(IRSL)Inserm Unit 1131ParisFrance Dana-Farber Cancer Institute BostonMAUSA Department of Hematopathology The University of Texas MD Anderson Cancer CenterHoustonTXUSA Princess Margaret Cancer Center TorontoONCanada High Resolution Electron Microscopy Facility The University of Texas MD Anderson Cancer CenterHoustonTXUSA Department of Bioinformatics&Computational Biology The University of Texas MD Anderson Cancer CenterHoustonTXUSA Department of Hematology The First Hospital Affiliated Harbin Medical UniversityHarbinChina Department of Lymphoma&Myeloma Research The University of Texas MD Anderson Cancer CenterHoustonTXUSA

Despite high initial response rates,acute myeloid leukemia(AML)treated with the BCL-2-selective inhibitor venetoclax(VEN)alone or in combinations commonly acquires *** performed gene/protein expression,metabolomic and methylation analyses of isogenic AML cell lines sensitive or resistant to VEN,and identified the activation of RAS/MAPK pathway,leading to increased stability and higher levels of MCL-1 protein,as a major acquired mechanism of VEN resistance.

关键词： acute myeloid acquired

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

引用

Signal Transduction and Targeted Therapy 2022年第5期7卷 1860-1860页

作者： Qi Zhang bridget riley-gillis.lina han Yannan Jia Alessia Lodi Haijiao Zhang Saravanan Ganesan Rongqing Pan Sergej N.Konoplev Shannon R.Sweeney Jeremy A.Ryan Yulia Jitkova Kenneth Dunner Jr Shaun E.Grosskurth Priyanka Vijay Sujana Ghosh Charles Lu Wencai Ma Stephen Kurtz Vivian R.Ruvolo Helen Ma Connie C.Weng Cassandra L.Ramage Natalia Baran Ce Shi Tianyu Cai Richard Eric Davis Venkata L.Battula Yingchang Mi Jing Wang Courtney D.DiNardo Michael Andreeff Jeffery W.Tyner Aaron Schimmer Anthony Letai Rose Ann Padua Carlos E.Bueso-Ramos Stefano Tiziani Joel Leverson Relja Popovic Marina Konopleva Department of Leukemia The University of Texas MD Anderson Cancer Center Houston TX USA Institute of Hematology Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China Department of Hematology The First Hospital Affiliated Harbin Medical University Harbin China AbbVie Inc. North Chicago IL USA Department of Nutritional Sciences Department of Pediatrics Department of Oncology Dell Medical School The University of Texas at Austin Austin TX 78712 USA Department of Cell Developmental & Cancer Biology Division of Hematology & Medical Oncology Knight Cancer Institute Oregon Health & Science University Portland OR USA Université de Paris Institut de la Recherche Saint-Louis (IRSL) Inserm Unit 1131 Paris France Dana-Farber Cancer Institute Boston MA USA Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA Princess Margaret Cancer Center Toronto ON Canada High Resolution Electron Microscopy Facility The University of Texas MD Anderson Cancer Center Houston TX USA Department of Bioinformatics & Computational Biology The University of Texas MD Anderson Cancer Center Houston TX USA Department of Lymphoma & Myeloma Research The University of Texas MD Anderson Cancer Center Houston TX USA

Correction to:Signal Transduction and Targeted Therapy(2022)7:1–13,https://***/10.1038/s41392-021-00870-3 In the original version of this article,given name of 4th author Yannan Jia was incorrectly published as Yanan *** original article has been *** Access This article is licensed under a Creative Commons Attribution 4.0 International License,which permits use,sharing,adaptation,distribution and reproduction in any medium or format,as long as you give appropriate credit to the original author(s)and the source.

关键词： myeloid Therapy resistance

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：